Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 140M | 149M | 120M | 96M | 60M |
| Gross Profit | 7M | 31M | 37M | 29M | 4M |
| Operating Income | -19M | -3M | 11M | 9M | -11M |
| EBITDA | -11M | 11M | 20M | 16M | -7M |
| Net Income | -141M | 560K | 128M | 11M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$12.49
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Avid Bioservices, Inc. (CDMO) is a Healthcare stock with a market cap of $798.90M. The stock last traded around $12.49. Baseline metrics include revenue growth of -6.3%, EPS growth of -24877.8%, a dividend yield of 0.0%. What stands out right now is revenue -6.3%, EPS -24877.8%, free cash flow +77.0% with operating margin -13.3% and ROIC -6.9%. Valuation sits in the middle of the pack at price/sales 5.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CDMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CDMO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CDMO Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CDMO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$59.7M
-37.7% YoY
FY Net Income
-$7.3M
-164.7% YoY
Free Cash Flow
$2.0M
-90.5% YoY
Revenue Growth
-6.3%
EPS Growth
-24877.8%
Gross Margin
5.2%
Net Margin
-100.6%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 140M | 149M | 120M | 96M | 60M |
| Gross Profit | 7M | 31M | 37M | 29M | 4M |
| Operating Income | -19M | -3M | 11M | 9M | -11M |
| EBITDA | -11M | 11M | 20M | 16M | -7M |
| Net Income | -141M | 560K | 128M | 11M | -7M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 38M | 39M | 126M | 170M | 36M |
| Total Assets | 337M | 451M | 430M | 266M | 108M |
| Total Liabilities | 276M | 262M | 255M | 188M | 66M |
| Shareholder Equity | 61M | 189M | 175M | 78M | 42M |
| Total Debt | 208M | 189M | 183M | 118M | 27M |
| Net Debt | 170M | 151M | 56M | -52M | -9M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
-81.3% YoY
Capital Expenditures
4M
+61.4% YoY
Free Cash Flow
2M
-90.5% YoY
Key ratios
Gross Margin
5.2%
Operating Margin
-13.3%
Net Margin
-100.6%
ROE
-112.4%
Debt / Equity
3.41x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.